Patents by Inventor Saurabh Wadhwa

Saurabh Wadhwa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High Concentration VEGF Receptor Fusion Protein Containing Formulations
    Publication number: 20240058418
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Application
    Filed: September 12, 2023
    Publication date: February 22, 2024
    Inventors: Kenneth S. Graham, Saurabh Wadhwa
  • High Concentration VEGF Receptor Fusion Protein Containing Formulations
    Publication number: 20210353714
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 18, 2021
    Inventors: Kenneth S. Graham, Saurabh WADHWA
  • High concentration VEGF receptor fusion protein containing formulations
    Patent number: 11103552
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: August 31, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kenneth S. Graham, Saurabh Wadhwa
  • Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
    Patent number: 11071780
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 27, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. Vitti, Kristine A. Erickson, Karen W. Chu, Stanley J. Wiegand, Jingtai Cao, Ivan B. Lobov, Saurabh Wadhwa, Kenneth S. Graham, Daniel Dix
  • METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
    Publication number: 20190117767
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: December 28, 2018
    Publication date: April 25, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
  • METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
    Publication number: 20170080086
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
  • METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
    Publication number: 20160144025
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: November 17, 2015
    Publication date: May 26, 2016
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
  • POLYMER-METAL CHELATOR CONJUGATES AND USES THEREOF
    Publication number: 20090092664
    Abstract: The present invention provides prodrugs comprising a polymer conjugated to a metal chelator via a disulfide bond. For example, D-penicillamine may be conjugated to a polymer (e.g., gelatin, chitosan, polyglutamic acid) via a linker, such as SPDP. Thus, the cellular delivery and pharmacokinetics of D-penicillamine can be substantially improved. Methods for the treatment of cancer using compositions of the present invention are also disclosed.
    Type: Application
    Filed: October 1, 2008
    Publication date: April 9, 2009
    Inventors: Russell J. Mumper, Anshul Gupte, Saurabh Wadhwa